Sodium oxybate
- Generic Name
- Sodium oxybate
- Brand Names
- Lumryz, Xyrem, Xywav
- Drug Type
- Small Molecule
- Chemical Formula
- C4H7NaO3
- CAS Number
- 502-85-2
- Unique Ingredient Identifier
- 7G33012534
- Background
Sodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of gamma-Hydroxybutyric acid, an endogenous cerebral inhibitory neurotransmitter and a metabolite of the inhibitory neurotransmitter GABA. Due to its physiological effects, sodium oxybate...
- Indication
Sodium oxybate is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. In the US and in Europe, the drug is approved for use in patients 7 years of age and older while in Canada, it is not recommended in children under the age of 18, unless clearly needed.
- Associated Conditions
- Cataplexy, Excessive Daytime Sleepiness
- Associated Therapies
- -
Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
- Target Recruit Count
- 314
- Registration Number
- NCT04648423
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 24
- Registration Number
- NCT04006925
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Kristina Simonyan
- Target Recruit Count
- 140
- Registration Number
- NCT03292458
- Locations
- 🇺🇸
Massachusetts Eye and Ear, Boston, Massachusetts, United States
Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Ramin Khatami
- Target Recruit Count
- 60
- Registration Number
- NCT02637648
A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Concert Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02215499
- Locations
- 🇬🇧
Quotient Clinical Ltd., Ruddington, Nottingham, United Kingdom
Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Christian Baumann
- Target Recruit Count
- 16
- Registration Number
- NCT02111122
- Locations
- 🇨🇭
Department of Neurology, Zurich, Switzerland
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
- Conditions
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT02063217
- Locations
- 🇺🇸
Washington University Medical School, Saint Louis, Missouri, United States
SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT02055898
- Locations
- 🇬🇧
Wellcome CRF, Imperial College, Hammersmith Campus, London, United Kingdom
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Kristina Simonyan
- Target Recruit Count
- 53
- Registration Number
- NCT01961297
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- University Hospital, Ghent
- Registration Number
- NCT01584934
- Locations
- 🇧🇪
Ghent University Hospital, Ghent, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.